Milene Fernandes

Milene Fernandes

Auto-generated profile, based on publicly available information

Milene Fernandes

CTI Clinical Trial and Consulting Services, Covington, KY

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 October 2013 in International Journal of Clinical Pharmacy
Verified
Journal Article
Closed access
PDF file
MFMilene Fernandes
Milene Fernandes
ALAndreia Leite
Andreia Leite
MBMaria Basto
Maria Basto
Miguel de Araújo NobreMiguel de Araújo Nobre
Miguel de Araújo Nobre
NVNuno Vieira
Nuno Vieira
PJPaulo Jorge
Paulo Jorge

22 November 2021 in Family Practice
Verified
Journal Article
Closed access
PDF file
MFMilene Fernandes
Milene Fernandes
INInês Neves
Inês Neves
JOJoana Oliveira
Joana Oliveira
OSOsvaldo Santos
Osvaldo Santos
PAPedro Vargues Aguiar
Pedro Vargues Aguiar
VMVasco Maria
Vasco Maria
Chronic benzodiazepine use is a challenge in primary care practice. Protocols to support safe discontinuation are still needed, especially in countries with high utilization rates. To evaluate the feasibility, effectiveness, and safety of a benzodiazepine discontinuation protocol in primary care setting. Nonrandomized, single-arm interventional study, at primary care units. Family physicians (FPs) recruited patients (18–85 years-old) with benzodiazepine dependence and chronic daily use ≥3 months. Patients with daily dosages ≥30 mg diazepam-equivalent, taking zolpidem, with a history of other substance abuse or major psychiatric disease were excluded. After the switch to diazepam, the dosage was gradually tapered according to a standardized protocol. Primary endpoint was the percentage of patients who stopped benzodiazepine at the intervention last visit. Dosage reduction, withdrawal symptoms, patients’ and FPs’ satisfaction with the protocol were evaluated. From 66 enrolled patients (74% female; 66.7% aged >64 years; median time of benzodiazepine use was 120 months), 2 withdrew due to medical reasons and 3 presented protocol deviations. Overall, 59.4% of participants successfully stopped benzodiazepine (60.7% when excluding protocol deviations). Men had higher probability of success (relative risk = 0.51, P = 0.001). A total of 31 patients reported at least 1 withdrawal symptom, most frequently insomnia and anxiety. Most of participating FP considered the clinical protocol useful and feasible in daily practice. Among patients completing the protocol, 77% were satisfied. For the patients who reduced dosage, 85% kept without benzodiazepines after 12 months. The discontinuation protocol with standardized dosage reduction was feasible at primary care and showed long-term effectiveness.

30 March 2022 in Frontiers in Psychiatry
Verified
Journal Article
Open access
JBJoão M. Bessa
João M. Bessa
SCSerafim Carvalho
Serafim Carvalho
ICInês B. Cunha
Inês B. Cunha
MFMilene Fernandes
Milene Fernandes
AMAna Matos-Pires
Ana Matos-Pires
VSVítor Santos
Vítor Santos
Guidance about treatment-resistant depression (TRD) in Portugal is very limited, even though depression prevalence is among the highest in European countries. A questionnaire was conducted, followed by two advisory boards with seven Portuguese psychiatry experts, to characterize and discuss MDD and TRD epidemiology, diagnosis, patient journey, treatment options, and unmet clinical needs. Consensus was reached on the main issues. In daily practice, TRD can be defined as moderate to severe MDD episodes with insufficient clinical improvement after two antidepressant treatments, taken in adequate doses and duration. TRD diagnosis and treatment are mostly decided by psychiatrists at public hospitals. Treatment type and duration must be adjusted to characteristics of the patient and the depressive episode, including symptoms, number of previous episodes, comorbidities, and previous treatment response and side effects. The most relevant objectives of TRD treatment are reaching response and remission, prevention of suicide, and improvement of quality of life, functionality, and wellbeing. Regarding pharmacotherapy, antidepressant switch occurs more frequently with non-response, while optimization, combination, and augmentation are considered for patients with partial response. Psychotherapy should be considered in parallel to pharmacological treatment. Brain stimulation techniques are underused. Lifelong treatment is required for recurrent or more chronic TRD episodes, but patient adherence is also poorer in these cases. In Portugal, TRD management is limited by lack of access to specialist care and to many treatment options. These aspects highlight that conventional pharmacotherapy does not lead to remission in many patients and that optimization strategies are frequently necessary to achieve satisfactory treatment outcomes.

13 January 2025 in Critical Care Explorations
Verified
Journal Article
Open access
RBRobert S. Jr Brown
Robert S. Jr Brown
RFRobert A. Md Fisher
Robert A. Md Fisher
RSRam M. Md Subramanian
Ram M. Md Subramanian
AGAdam Griesemer
Adam Griesemer
MFMilene PharmD Fernandes
Milene PharmD Fernandes
MCMichael Curtis
Michael Curtis
OBJECTIVES: To systematically review the safety and efficacy of nonbiological (NBAL) or biological artificial liver support systems (BAL) and whole-organ extracorporeal liver perfusion (W-ECLP) systems, in adults with acute liver failure (ALF) and acute-on-chronic liver failure (ACLF). DATA SOURCES: Eligible NBAL/BAL studies from PubMed/Embase searches were randomized controlled trials (RCTs) in adult patients with ALF/ACLF, greater than or equal to ten patients per group, reporting outcomes related to survival, adverse events, transplantation rate, and hepatic encephalopathy, and published in English from January 2000 to July 2023. Separately, we searched for studies evaluating W-ECLP in adult patients with ALF or ACLF published between January1990 and July 2023. STUDY SELECTION AND DATA EXTRACTION: Two researchers independently screened citations for eligibility and, of eligible studies, retrieved data related to study characteristics, patients and interventions, outcomes definition, and intervention effects. The Cochrane Risk of Bias 2 tool and Joanna Briggs Institute checklists were used to assess individual study risk of bias. Meta-analysis of mortality at 28–30 days post-support system initiation and frequency of at least one serious adverse event (SAE) generated pooled risk ratios (RRs), based on random (mortality) or fixed (SAE) effects models. DATA SYNTHESIS: Of 17 trials evaluating NBAL/BAL systems, 11 reported 28–30 days mortality and five reported frequency of at least one SAE. Overall, NBAL/BAL was not statistically associated with mortality at 28–30 days (RR, 0.85; 95% CI, 0.67–1.07; p = 0.169) or frequency of at least one SAE (RR, 1.15; 95% CI, 0.99–1.33; p = 0.059), compared with standard medical treatment. Subgroup results on ALF patients suggest possible benefit for mortality (RR, 0.67; 95% CI, 0.44–1.03; p = 0.069). From six reports of W-ECLP (12 patients), more than half (58%) of severe patients were bridged to transplantation and survived without transmission of porcine retroviruses. CONCLUSIONS: Despite no significant pooled effects of NBAL/BAL devices, the available evidence calls for further research and development of extracorporeal liver support systems, with larger RCTs and optimization of patient selection, perfusion durability, and treatment protocols.

1 December 2013 in Revista Portuguesa de Cardiologia
Verified
Journal Article
Open access
MOMário Martins Oliveira
Mário Martins Oliveira
MFMilene Fernandes
Milene Fernandes
JPJoão Primo
João Primo
HRHipólito Reis
Hipólito Reis
Paulo NicolaPaulo Nicola
Paulo Nicola
With expanding indications for cardiac implantable electronic devices (CIEDs) capable of treating bradycardias, complex cardiac tachyarrhythmias and heart failure, the number of patients requiring regular long-term specialized care is growing rapidly. Currently, routine face-to-face follow-up consultations for patients with CIEDs are a significant burden on hospital services. Remote telemonitoring appears to offer a safe and effective alternative to conventional follow-up in this area. The Medtronic CareLink Network enables remote monitoring of CIED patients, and thus has the potential to improve the efficiency of medical care in this population. The objective of the PORTLink (PORTuguese Research on Telemonitoring with CareLink) multicenter randomized trial is to assess the safety, efficacy and costs of remote CIED monitoring compared to traditional face-to-face follow-up. It will evaluate aspects such as physicians' and patients' acceptance of and satisfaction with reviewing device data via the website, the complexity for troubleshooting calls to the support center, the use of emergency resources by symptomatic patients, the incidence of unscheduled consultations after remote interrogations, levels of anxiety, depression and quality of life, and the main resources used by the CareLink system. Approximately 200 patients will be randomized in up to five centers, with clinical follow-up of 12 months. Enrollment began in 2012 and is expected to be completed in early 2014.

30 June 2014
Verified
Journal Article
Closed access
ABAna Bispo
Ana Bispo
MFMilene Fernandes
Milene Fernandes
CTCristina Toscano
Cristina Toscano
TMTeresa Marques
Teresa Marques
DMDomingos Machado
Domingos Machado
AWAndré Weigert
André Weigert